Bispecific peptide - Immune-Onc Therapeutics
Latest Information Update: 30 Apr 2021
At a glance
- Originator Immune-Onc Therapeutics
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 05 Apr 2021 Preclinical trials in Cancer in USA Unspecified) (Immune-Onc Therapeutics pipeline, April 2021)